141 related articles for article (PubMed ID: 11078325)
1. Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH.
Fahnoe DC; Knapp J; Johnson GD; Ahn K
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S22-5. PubMed ID: 11078325
[TBL] [Abstract][Full Text] [Related]
2. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
Raoch V; Martinez-Miguel P; Arribas-Gomez I; Rodriguez-Puyol M; Rodriguez-Puyol D; Lopez-Ongil S
Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
[TBL] [Abstract][Full Text] [Related]
3. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum.
Emoto N; Yanagisawa M
J Biol Chem; 1995 Jun; 270(25):15262-8. PubMed ID: 7797512
[TBL] [Abstract][Full Text] [Related]
4. Soluble human endothelin-converting enzyme-1: expression, purification, and demonstration of pronounced pH sensitivity.
Ahn K; Herman SB; Fahnoe DC
Arch Biochem Biophys; 1998 Nov; 359(2):258-68. PubMed ID: 9808768
[TBL] [Abstract][Full Text] [Related]
5. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
Yap EY; Battistini B; McKay KO
Br J Pharmacol; 2000 Jan; 129(1):170-6. PubMed ID: 10694217
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Kuzmich S; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S69-71. PubMed ID: 8587471
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor.
Shetty SS; Savage P; DelGrande D; De Lombaert S; Jeng AY
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S68-70. PubMed ID: 9595403
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor.
Feldman DL; Mogelesky TC; Chou M; Jeng AY
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S342-5. PubMed ID: 11078415
[TBL] [Abstract][Full Text] [Related]
9. Molecular pharmacology of endothelin converting enzymes.
Turner AJ; Murphy LJ
Biochem Pharmacol; 1996 Jan; 51(2):91-102. PubMed ID: 8615890
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-2-converting enzyme from human renal adenocarcinoma cells is a phosphoramidon-sensitive, membrane-bound metalloprotease.
Shinmi O; Yorimitsu K; Moroi K; Nishiyama M; Sugita Y; Saito T; Inagaki Y; Masaki T; Kimura S
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S61-4. PubMed ID: 7510000
[TBL] [Abstract][Full Text] [Related]
12. Effects of endothelin-converting enzyme inhibitors on hemolysate-induced morphological changes and production of endothelin-1 in bovine cerebrovascular endothelial cells.
Kwan AL; Lin CL; Chang CZ; Winardi D; Yen CP; Howng SL; Jeng AY
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S160-2. PubMed ID: 11078366
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
[TBL] [Abstract][Full Text] [Related]
14. Effects of dual endothelin-converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleukin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells.
Pelletier S; Battistini B; Jeng AY; Sirois P
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S10-2. PubMed ID: 9595386
[TBL] [Abstract][Full Text] [Related]
15. Characterization of phosphoramidon-sensitive metalloproteinases with endothelin-converting enzyme activity in porcine lung membrane.
Sawamura T; Shinmi O; Kishi N; Sugita Y; Yanagisawa M; Goto K; Masaki T; Kimura S
Biochim Biophys Acta; 1993 Feb; 1161(2-3):295-302. PubMed ID: 8431480
[TBL] [Abstract][Full Text] [Related]
16. In vivo role of endothelin-converting enzyme-1 as examined by adenovirus-mediated overexpression in rats.
Télémaque S; Emoto N; deWit D; Yanagisawa M
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S548-50. PubMed ID: 9595539
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.
Jeng AY; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Trapani AJ
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S36-9. PubMed ID: 11078330
[TBL] [Abstract][Full Text] [Related]
18. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
[TBL] [Abstract][Full Text] [Related]
19. Big endothelin analogues with inhibitory activity on endothelin-converting enzyme-1.
Takayanagi R; Liu W; Ito T; Ohnaka K; Nawata H
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S62-3. PubMed ID: 9595401
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme.
Woods M; Mitchell JA; Wood EG; Barker S; Walcot NR; Rees GM; Warner TD
Mol Pharmacol; 1999 May; 55(5):902-9. PubMed ID: 10220569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
